Recent progress and missing gaps to achieve goal in the care of systemic sclerosis–associated interstitial lung disease

Varga J Trojanowska M Kuwana M . Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities. J Scleroderma Relat Disord 2017; 2: 137–152.

Elhai M Meune C Boubaya M , et al. Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis 2017; 76(11): 1897–1905.

Fischer A Zimovetz E Ling C , et al. Humanistic and cost burden of systemic sclerosis: a review of the literature. Autoimmun Rev 2017; 16(11): 1147–1154.

Tashkin DP Elashoff R Clements PJ , et al. Cyclo-phosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655–2666.

Tashkin DP Roth MD Clements PJ , et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 2016; 4: 708–719.

Fernandez-Codina A Walker KM Pope JE . Treatment algorithms for systemic sclerosis according to experts. Arthritis Rheumatol 2018; 70(11): 1820–1828.

Wollin L Distler JHW Denton CP , et al. Rationale for the evaluation of nintedanib as a treatment for systemic sclerosis—associated interstitial lung disease. J Scleroderma Relat Disord 2019; 4: 212–218.

Kuwana M Azuma A . Nintedanib: new indication for systemic sclerosis-associated interstitial lung disease. Mod Rheumatol. Epub ahead of print 20 December 2019.

Distler O Highland KB Gahlemann M , et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med 2019; 380: 2518–2528.

Hoffmann-Vold AM Maher TM Philpot EE , et al. Evidence-based European consensus statements for the identification and management of interstitial lung disease in systemic sclerosis. Lancet Rheumatol 2020. Published: January 14, 2020 DOI: 10.1016/S2665-9913(19)30144-4.

Herzog EL Mathur A Tager AM , et al. Interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct? Arthritis Rheumatol 2014; 66(8): 1967–1978.

Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G Anstrom KJ , et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012; 366: 1968–1977.

Man A Davidyock T Ferguson LT , et al. Changes in forced vital capacity over time in systemic sclerosis: application of group-based trajectory modelling. Rheumatology 2015; 54(8): 1464–1471.

Kuwana M Shirai Y Takeuchi T . Elevated serum Krebs von den Lungen-6 in early disease predicts subsequent deterioration of pulmonary function in patients with systemic sclerosis and interstitial lung disease. J Rheumatol 2016; 43(10): 1825–1831.

Huang J Maier C Zhang Y , et al. Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis. Ann Rheum Dis 2017; 76(11): 1941–1948.